Innovent Biologics Inc (HKEX: 01801), a biopharmaceutical company that develops, manufactures and commercialises medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced on Tuesday that it will present multiple clinical study results of mazdutide at the American Diabetes Association's(R) (ADA) 84th Scientific Sessions in Orlando from 21 to 24 June 2024.
Innovent will share the results from the first phase 3 study of mazdutide in Chinese adults with obesity and overweight (GLORY-1), an exploratory analysis of GLORY-1 on liver steatosis, as well as a Phase 2 study of mazdutide 9 mg in adults with obesity during one oral presentation and two posters.
Dr Lei Qian, Innovent vice president of Clinical Development, stated: "We are excited to announce the results of GLORY-1 at ADA scientific sessions. Mazdutide is the first GLP-1R/GCGR dual agonist that succeeded in a Phase 3 registration study for people with overweight/obesity. Meanwhile, the strong results of a Phase 2 study of mazdutide 9mg in Chinese adults with moderate-to-severe obesity will also be released at ADA, and the corresponding Phase 3 GLORY-2 is currently ongoing. Mazdutide is anticipated to provide an individualised, effective and safe weight management option for people with overweight or obesity at different severities."
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient